Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.80
PODD's Cash to Debt is ranked lower than
56% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. PODD: 0.80 )
Ranked among companies with meaningful Cash to Debt only.
PODD' s 10-Year Cash to Debt Range
Min: 0.49  Med: 1.17 Max: N/A
Current: 0.8
Equity to Asset 0.23
PODD's Equity to Asset is ranked lower than
90% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. PODD: 0.23 )
Ranked among companies with meaningful Equity to Asset only.
PODD' s 10-Year Equity to Asset Range
Min: -2.37  Med: 0.27 Max: 0.73
Current: 0.23
-2.37
0.73
F-Score: 6
Z-Score: 2.80
M-Score: -3.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -9.19
PODD's Operating margin (%) is ranked lower than
72% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.48 vs. PODD: -9.19 )
Ranked among companies with meaningful Operating margin (%) only.
PODD' s 10-Year Operating margin (%) Range
Min: -43010  Med: -64.87 Max: -4.26
Current: -9.19
-43010
-4.26
Net-margin (%) -15.30
PODD's Net-margin (%) is ranked lower than
75% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. PODD: -15.30 )
Ranked among companies with meaningful Net-margin (%) only.
PODD' s 10-Year Net-margin (%) Range
Min: -43272  Med: -86.32 Max: -17.84
Current: -15.3
-43272
-17.84
ROE (%) -55.35
PODD's ROE (%) is ranked lower than
87% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. PODD: -55.35 )
Ranked among companies with meaningful ROE (%) only.
PODD' s 10-Year ROE (%) Range
Min: -178.71  Med: -81.74 Max: -49.42
Current: -55.35
-178.71
-49.42
ROA (%) -14.17
PODD's ROA (%) is ranked lower than
76% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.43 vs. PODD: -14.17 )
Ranked among companies with meaningful ROA (%) only.
PODD' s 10-Year ROA (%) Range
Min: -106.29  Med: -54.35 Max: -17.45
Current: -14.17
-106.29
-17.45
ROC (Joel Greenblatt) (%) -57.33
PODD's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. PODD: -57.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PODD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1016.01  Med: -217.31 Max: -65.62
Current: -57.33
-1016.01
-65.62
Revenue Growth (3Y)(%) 16.80
PODD's Revenue Growth (3Y)(%) is ranked higher than
87% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. PODD: 16.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PODD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 19.95 Max: 101.6
Current: 16.8
0
101.6
EBITDA Growth (3Y)(%) -15.10
PODD's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. PODD: -15.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PODD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -72.6  Med: -34.05 Max: 25.9
Current: -15.1
-72.6
25.9
EPS Growth (3Y)(%) -1.70
PODD's EPS Growth (3Y)(%) is ranked lower than
65% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. PODD: -1.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PODD' s 10-Year EPS Growth (3Y)(%) Range
Min: -71  Med: -22.70 Max: 31.2
Current: -1.7
-71
31.2
» PODD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

PODD Guru Trades in Q3 2014

Louis Moore Bacon 130,000 sh (New)
Pioneer Investments 326,337 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
PRIMECAP Management 1,956,456 sh (-0.08%)
Mariko Gordon 1,725,296 sh (-0.81%)
Ken Fisher 9,588 sh (-49.24%)
» More
Q4 2014

PODD Guru Trades in Q4 2014

Joel Greenblatt 31,602 sh (New)
PRIMECAP Management 1,974,456 sh (+0.92%)
Ken Fisher 9,588 sh (unchged)
Louis Moore Bacon Sold Out
Mariko Gordon 1,516,854 sh (-12.08%)
Pioneer Investments 205,238 sh (-37.11%)
» More
Q1 2015

PODD Guru Trades in Q1 2015

Pioneer Investments 315,566 sh (+53.76%)
PRIMECAP Management 2,831,635 sh (+43.41%)
Mariko Gordon 2,037,999 sh (+34.36%)
Ken Fisher 9,588 sh (unchged)
Joel Greenblatt Sold Out
» More
Q2 2015

PODD Guru Trades in Q2 2015

Steven Cohen 34,000 sh (New)
PRIMECAP Management 5,032,572 sh (+77.73%)
Pioneer Investments 341,232 sh (+8.13%)
Mariko Gordon 2,058,307 sh (+1.00%)
Ken Fisher 9,588 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PODD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 2000.00
PODD's Forward P/E is ranked lower than
100% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.74 vs. PODD: 2000.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 23.96
PODD's P/B is ranked lower than
98% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. PODD: 23.96 )
Ranked among companies with meaningful P/B only.
PODD' s 10-Year P/B Range
Min: 3.13  Med: 13.68 Max: 1235
Current: 23.96
3.13
1235
P/S 5.89
PODD's P/S is ranked lower than
77% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. PODD: 5.89 )
Ranked among companies with meaningful P/S only.
PODD' s 10-Year P/S Range
Min: 1.25  Med: 6.16 Max: 25.53
Current: 5.89
1.25
25.53
POCF 247.58
PODD's POCF is ranked lower than
96% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.43 vs. PODD: 247.58 )
Ranked among companies with meaningful POCF only.
PODD' s 10-Year POCF Range
Min: 183.69  Med: 585.50 Max: 99999999.99
Current: 247.58
183.69
99999999.99
Current Ratio 3.87
PODD's Current Ratio is ranked higher than
74% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. PODD: 3.87 )
Ranked among companies with meaningful Current Ratio only.
PODD' s 10-Year Current Ratio Range
Min: 0.67  Med: 4.74 Max: 8.04
Current: 3.87
0.67
8.04
Quick Ratio 3.42
PODD's Quick Ratio is ranked higher than
76% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. PODD: 3.42 )
Ranked among companies with meaningful Quick Ratio only.
PODD' s 10-Year Quick Ratio Range
Min: 0.56  Med: 4.32 Max: 7.56
Current: 3.42
0.56
7.56
Days Inventory 38.45
PODD's Days Inventory is ranked higher than
91% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. PODD: 38.45 )
Ranked among companies with meaningful Days Inventory only.
PODD' s 10-Year Days Inventory Range
Min: 28.31  Med: 61.70 Max: 111.63
Current: 38.45
28.31
111.63
Days Sales Outstanding 40.85
PODD's Days Sales Outstanding is ranked higher than
83% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.01 vs. PODD: 40.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
PODD' s 10-Year Days Sales Outstanding Range
Min: 48.85  Med: 73.05 Max: 1022
Current: 40.85
48.85
1022

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 82.53
PODD's Price/Tangible Book is ranked lower than
97% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.27 vs. PODD: 82.53 )
Ranked among companies with meaningful Price/Tangible Book only.
PODD' s 10-Year Price/Tangible Book Range
Min: 3.41  Med: 19.59 Max: 1123
Current: 82.53
3.41
1123
Price/Median PS Value 0.96
PODD's Price/Median PS Value is ranked higher than
62% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. PODD: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
PODD' s 10-Year Price/Median PS Value Range
Min: 0.21  Med: 1.02 Max: 3.15
Current: 0.96
0.21
3.15
Earnings Yield (Greenblatt) (%) -1.82
PODD's Earnings Yield (Greenblatt) (%) is ranked lower than
71% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. PODD: -1.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PODD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -5.1  Med: 0.00 Max: 0
Current: -1.82
-5.1
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 309 359 419
EPS($) -0.87 -0.50 -0.14
EPS without NRI($) -0.87 -0.50 -0.14

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:GOV.Germany,
Insulet Corp is a Delaware corporation formed in July 2000. The Company is engaged in the development, manufacturing and sale of OmniPod Insulin Management System. The OmniPod System is a disposable tubeless OmniPod worn on the body for approximately three days at a time. OmniPod Insulin Management System consists of disposable tubeless OmniPod worn on the body for approximatley three days at a time. The OmniPod System features two devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. In October 2005 the Company began its commercial sale of OmniPod System in the United States. The Company sells OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through distribution partners. The OmniPod System is available in Europe through distribution partner, Ypsomed Distribution AG and in Canada through the distribution partner GlaxoSmithKline. The Company's sales and marketing effort is focused on generating demand and acceptance of the OmniPod System among diabetes practitioners, academic medical centers, clinics, insulin-dependent diabetes patients, third-party payors, government agencies, and third-party distributors. The marketing strategy is to build awareness for the benefits of the OmniPod System through education programs, social networking, patient demonstration programs, support materials, media advertisements and events at the national, regional and local levels. As of December 31, 2013, the Company had obtained 15 issued United States patents, and had 8 additional pending U.S. patent applications. It has registered the trademarks OMNIPOD, INSULET and the OMNIPOD design with the United States Patent and Trademark Office on the Principal Register. The OmniPod System competes with Medtronic MiniMed, Animas Corporation, Tandem Diabetes Care, Inc. and Roche Diagnostics, a division of F. Hoffmann-La Roche, Ltd.
» More Articles for PODD

Headlines

Articles On GuruFocus.com
Insulet Corporation to Announce Second Quarter 2015 Financial Results on July 30, 2015 Jul 08 2015 
Insulet Announces Organizational Changes Jun 30 2015 
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Insule Jun 26 2015 
Mariko Gordon's Trades In Q1 2015 Jun 12 2015 
Weekly CEO Buys Highlight: NUVA, HK, BKFS, PODD, CLF Jun 02 2015 
Insulet Corp. (PODD) President and CEO Duane Desisto sells 24,400 Shares Feb 18 2011 
Insulet Corp. (PODD) President and CEO Duane Desisto sells 27,000 Shares Feb 15 2011 
Insulet Corp. Reports Operating Results (10-Q) Aug 09 2010 
Insulet Corp. Reports Operating Results (10-Q) Aug 09 2010 
Insulet Corp. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
INSULET CORP Financials Aug 25 2015
10-Q for Insulet Corp. Aug 14 2015
Edited Transcript of PODD earnings conference call or presentation 12-Aug-15 8:30pm GMT Aug 12 2015
Insulet Corp Earnings Call scheduled for 4:30 pm ET today Aug 12 2015
Insulet reports 2Q loss Aug 12 2015
Insulet reports 2Q loss Aug 12 2015
Insulet Reports Second Quarter 2015 Financial Results Aug 12 2015
INSULET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 12 2015
Insulet Reports Second Quarter 2015 Financial Results Aug 12 2015
Q2 2015 Insulet Corp Earnings Release - After Market Close Aug 12 2015
Insulet Provides Update Regarding Release of Second Quarter Results Aug 10 2015
INSULET CORP Files SEC form 8-K, Regulation FD Disclosure Aug 10 2015
Insulet Provides Update Regarding Release of Second Quarter Results Aug 10 2015
INSULET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jul 30 2015
Insulet Reports Preliminary Second Quarter 2015 Revenue Results Jul 29 2015
Insulet Reports Preliminary Second Quarter 2015 Revenue Results Jul 29 2015
INSULET CORP Files SEC form 8-K, Change in Directors or Principal Officers Jul 29 2015
Insulet Appoints Jessica Hopfield, PhD, to Board of Directors Jul 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK